BioMimetic Aims To Complete Bone Graft Study Enrollment By Year-End
This article was originally published in The Gray Sheet
Executive Summary
BioMimetic Therapeutics is hoping enrollment in an ongoing pivotal trial for its Augment Bone Graft will be complete by year-end despite a recent slowdown in registration